Endocrine Abstracts

Gastroenteropancreatic Neuroendocrine Tumours (NETs) may lead to gastrointestinal symptoms directly or as a result of their treatment, for example surgical resection and/or somatostatin analogues (SSA). When these symptoms become severe, patients may develop a reduced ability to successfully digest and absorb nutrients in the diet. This may be specific due the area of resection, e.g. vitamin B12, or secondary from medication, e.g. SSA induced pancreatic exocrine insufficiency ...